Intervacc announces the outcome of the fully secured rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, RELEASE OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE PURSUANT TO APPLICABLE LAW. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Stockholm, June 8, 2023The subscription period of the rights issue in Intervacc AB (publ) ("Intervacc" or the "Company") ended on June 7, 2023. The subscription ratio in the rights issue amounted to 158 percent. Guarantee commitments made in connection with the rights issue will thus not be utilized. Through the rights issue, Intervacc will receive approximately SEK 104 million before deduction of issue costs.
- The subscription ratio in the rights issue amounted to 158 percent.
- 23,063,970 shares, corresponding to approximately 91 percent of the rights issue, were subscribed for by exercise of subscription rights and 2,181,451 shares, corresponding to approximately 9 percent of the rights issue, were subscribed for without subscription rights.
- No guarantee commitments have been utilized.
- The purpose of the rights issue is to finance accelerated commercialization of Strangvac, regulatory processes for Strangvac in the US, Australia and New Zealand with the aim of obtaining marketing authorisation, as well as continued development of product candidates in the Company's project pipeline (INV274 and INV412).
Through the rights issue, the Company will receive approximately SEK 104 million before deduction of issue costs, which amount to approximately SEK 12 million. The rights issue consists of 25,245,421 new shares. The subscription price was SEK 4.10 per new share and the subscription period ended on June 7, 2023. 23,063,970 shares, corresponding to approximately 91 percent of the rights issue, were subscribed for by exercise of subscription rights and 2,181,451 shares, corresponding to approximately 9 percent of the rights issue, were subscribed for without subscription rights. The rights issue is thus fully subscribed and no guarantee commitments have been utilized.
Through the rights issue, Intervacc's share capital will increase by approximately SEK 50,490,845.41, from approximately SEK 100,981,692.83 to approximately SEK 151,472,538.24 and the total number of shares will increase by 25,245,421, from 50,490,843 shares to 75,736,264 shares.
Allotment of shares subscribed for without subscription rights will be made in accordance with the principles outlined in the prospectus. Around June 9, 2023, a settlement note will be sent to those who have received allotment of shares as confirmation of the allotment of shares subscribed for without subscription rights. No confirmation will be sent to subscribers who received no allotment. Payment for subscribed and allocated shares is to be made in cash in accordance with the instructions on the settlement note sent to the subscriber. Nominee-registered shareholders will receive a notification of allotment in accordance with the respective nominee's procedures.
The last day for trading in paid-up subscribed shares (BTA) is June 13, 2023. The first day of trading in the new shares on Nasdaq First North Growth Market is expected to be on or around June 19, 2023.
In conjunction with the rights issue, the Company has engaged Carnegie Investment Bank AB (publ) as Sole Global Coordinator and Bookrunner, and Cirio Advokatbyrå AB as legal advisor.
For more information please contact:
Andreas Andersson, CEO
Phone: +46 (0)8 120 10601, Cell: +46 (0)73 335 99 70
E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above, at 20.05 CEST on June 8, 2023
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: [email protected],Phone: +46 (0)8 - 684 211 10
The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares, paid subscribed share, subscription rights or other securities in the Company. No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for shares in the Company have only been made through the prospectus that the Company has published in an authorised manner.
The information in this press release may not be published or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "USA"), Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law. This press release does not constitute an offer of invitation to acquire or subscribe for shares or other securities in the USA. No shares, paid subscribed share, subscription rights or other securities issued by the Company (the "Securities") have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the USA other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the USA. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission, any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the rights issue or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.
This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. In any EEA Member State, other than Sweden, this communication is only addressed to and is only directed at "qualified investors" in that Member State within the meaning of the Prospectus Regulation.
In the United Kingdom, this document and any other materials in relation to the Securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the Prospectus Regulation which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.